Consolidation with 90 Yttrium-ibritumomab tiuxetan after bendamustine and rituximab for relapsed follicular lymphoma.
Miura K, Tsujimura H, Masaki Y, Iino M, Takizawa J, Maeda Y, Yamamoto K, Tamura S, Yoshida A, Yagi H, Yoshida I, Kitazume K, Masunari T, Choi I, Kakinoki Y, Suzuki R, Yoshino T, Nakamura S, Hatta Y, Yoshida T, Kanno M.
Miura K, et al. Among authors: yoshida i, yoshida t, yoshida a.
Hematol Oncol. 2021 Feb;39(1):51-59. doi: 10.1002/hon.2809. Epub 2020 Oct 7.
Hematol Oncol. 2021.
PMID: 32978820
Clinical Trial.